COVID-19 Prevalence in HIV-infected Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-04

Study Completion Date

2022-05-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them figuring different kinds of immune deficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, those patients with uncontrolled viral load and/or low CD4 cell counts, remain at higher risk of severe COVID infection. In this context, the primary objective of our study is aimed at evaluating the prevalence of SARS-CoV-2 antibodies in a cohort of HIV-infected patients followed-up in an HIV-infection care center. Secondary objectives are: evaluating whether the antibodies are protective or not, the kinetic of these antibodies, and HIV associated factors with the presence of antibodies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 and HIV Patients

NCT04523012

Covid19

COMPLETED

COVID-19 in Patients With HIV

NCT04333953

HIV/AIDS COVID-19 SARS-CoV-2

COMPLETED

Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV

NCT06258122

HIV Infections

RECRUITING

Missed Opportunities for HIV Screening in General Practice

NCT07303114

HIV Infections

RECRUITING

Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension

NCT00845013

HIV Infection Pulmonary Hypertension Endothelial Function +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-infected patients

All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination

Blood Sample

Intervention Type OTHER

Blood Sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults (\> 18 years)
* HIV-infected patients
* subjects with social insurance
* subjects able to understand study purposes, and to give a written and informed consent

Exclusion Criteria

* subjects unable to understand informations on the study, and to provide informed consent
* subjects under guardianship or curatorship
* subjects under judicial protection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No